What are WNT5A antibodies?
Anti-WNT5A antibodies are immunoglobulins that specifically recognize and bind WNT5A, the gene encoding Protein Wnt-5a in humans. In research, these antibodies are used to detect and localize the protein in tissue samples, cell lysates, and cultured cells. As a ligand for Frizzled-family receptors, Wnt-5a can activate or suppress canonical Wnt/beta-catenin signaling depending on which co-receptor it engages, giving it context-dependent roles across development and tissue homeostasis. Dysregulated Wnt-5a signaling has been linked to tumor progression, skeletal development, and chronic inflammatory conditions, making it a frequent target in cancer and developmental biology research.
Catalog highlights and purchasing considerations
About the Biocompare WNT5A antibody catalog
The Biocompare antibody search tool lists anti-WNT5A antibodies from a wide range of suppliers, available as polyclonal, monoclonal, and recombinant formats. Listings may also appear under the common name Wnt-5a or the full gene name Wingless-Type MMTV Integration Site Family, Member 5A. Western blot and immunohistochemistry are the most common validated applications, followed by ELISA. Several WNT5A antibodies mentioned here have been cited across a range of cancer and developmental biology research, including studies on chemoresistance in lung cancer, neuronal and odontogenic differentiation, and synovial inflammation in osteoarthritis.
Considerations when choosing a WNT5A antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria, such as clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method, should also guide the decision. Supplier-provided validation data, including western blot bands at the expected molecular weight, IHC staining patterns consistent with known tissue distribution, and knockout or knockdown controls, is widely regarded as the most reliable final check before purchase.